Inflection Point For Regen Med Lauded At London ARM Meeting
Executive Summary
Insights from the Alliance for Regenerative Medicine's fifth annual EU Advanced Therapies Investor Day, held in London in November 2017.
You may also be interested in...
TxCell: Regen Med Firm's CEO Starts From Scratch
Since becoming CEO of TxCell two years ago, Stéphane Boissel has reorganized the R&D plan, restructured and reduced the head count and put the company on the road to scalable manufacturing of CAR-T regulatory cells. And he has put strategic partnerships on the agenda. It is a big change from the situation 12 months ago, he told In Vivo during the Annual European Advanced Therapies Investor Day.
New Payment And Financing Models For Curative Regenerative Medicines
Cell and gene therapies that have the potential to cure require new approaches to value assessment, payment and financing. In the second of a series, the Alliance for Regenerative Medicine identifies potential payment models, highlights key stakeholder concerns and identifies the barriers that must be addressed to enable their integration across the health care system.
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.